World's First! Zhongnan Hospital Modular Bioartificial Liver Named Among 2026 Hubei Top 10 Medical-Engineering Innovation Achievements

Background

Acute liver failure is a rapidly progressing condition in which the liver loses its ability to perform critical tasks such as removing toxins from the blood, producing essential proteins, and maintaining metabolic balance. Without effective intervention, it carries high mortality. Liver transplantation remains the definitive treatment for many cases, yet donor organ shortages limit its availability, creating demand for temporary support therapies that can bridge patients to recovery or transplantation.

On September 19, 2026, the finals of the 2026 Hubei Provincial Medical-Engineering Innovation Development Competition) took place at the Wuhan Optics Valley Convention and Exhibition Center. The event evaluated projects across categories including high-end medical equipment. One selected innovation came from the Transplant Medicine Center at Zhongnan Hospital of Wuhan University.

What was achieved

The modular bioartificial liver integration platform developed by the team of Professors Ye Qifa and Zhong Zibiao (also referred to as Zibiao Zhong) was named one of the 2026 Hubei Top 10 Medical-Engineering Innovation Achievements. Official coverage describes the system as the world’s first high-end medical device of its kind. It is reported to fill a technological gap in the field of extracorporeal multi-functional support therapy for acute liver failure by providing a bridge for critically ill patients, creating a window for either liver function reversal or preparation for transplantation.

Clinical data associated with the system showed that the one-year survival rate for patients with severe liver failure increased from 26.3% to 55%. The project, which spanned more than ten years of research focused on liver and gallbladder surgery and translational medicine, overcame multiple technical challenges including toxin adsorption materials, cell microcarriers, high-density culture of human-derived hepatocytes, cell activity maintenance, and automated control.

The achievement is attributed to a closed-loop medical-engineering collaboration mechanism involving universities, enterprises, and the Hubei Provincial Clinical Research Center for Natural Polymer Biological Liver. The team has obtained more than 20 authorized invention patents, published hundreds of high-level academic papers, received the first prize of the Hubei Provincial Technical Invention Award, and facilitated the transformation of multiple core patents.

How it works

Bioartificial liver systems operate outside the body to temporarily replace some functions of a failing liver. In this modular integration platform, the patient’s blood undergoes processing in an extracorporeal circuit. Plasma or blood components are directed through a bioreactor containing high densities of functional human-derived hepatocytes. These living cells actively perform liver-like tasks: clearing toxins through specialized adsorption materials, synthesizing proteins, and supporting metabolic functions that the patient’s own liver can no longer sustain.

The modular design integrates several components, including automated systems to maintain cell viability, precise environmental controls, and integration of detoxification and synthetic modules. After passing through the bioreactor, the treated blood components are returned to the patient. Related phase 1 clinical research has utilized an immortalized L-02 human fetal hepatocyte line within an optimized bioreactor. The approach aims to stabilize the patient, reduce toxin levels, improve coagulation and other parameters, and extend the time available for native liver recovery or transplantation.

What it means for international patients

Zhongnan Hospital maintains an International Medical Department that offers services to overseas patients. Established to handle high-end medical care, the department provides appointment-based consultations, specialist access, green channels for timely care, multidisciplinary management, and dedicated facilities in a comfortable environment. It supports coordination with international insurance providers and delivers one-stop services drawing on the hospital’s broader clinical resources.

International patients with severe liver conditions interested in advanced support therapies, including those developed by the transplant team, should contact the hospital’s International Medical Department directly. Eligibility for any specific treatment, including this bioartificial liver platform, current availability, regulatory status, and suitability must be confirmed through individual medical evaluation by the hospital’s specialists. No assumptions regarding access or outcomes for international patients can be made without direct verification.

About the hospital

Zhongnan Hospital of Wuhan University is a Grade III Class A (tertiary A) comprehensive hospital located at 169 East Lake Road, Wuchang District, Wuhan, Hubei Province, adjacent to East Lake. Founded in 1956, it integrates medical care, education, research, and public emergency rescue services. The facility has more than 3,300 licensed beds and is affiliated with Wuhan University.

It hosts nationally recognized clinical key disciplines including gastroenterology, general surgery, critical care medicine, and oncology. The hospital is home to the Transplant Medicine Center, the Institute of Hepatobiliary Diseases, the Hubei Provincial Clinical Research Center for Natural Polymer Biological Liver, and serves as the National Quality Control Center for Donated Organ Procurement. It established its International Medical Department to provide specialized services for international and VIP patients, with facilities located on floors 24-25 of Building 4.